- Home
- CNEY vs PTIX Comparison
CNEY vs PTIX Comparison
Compare CNEY & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNEY
- PTIX
- Stock Information
- Founded
- CNEY 2018
- PTIX 1994
- Country
- CNEY China
- PTIX United States
- Employees
- CNEY N/A
- PTIX N/A
- Industry
- CNEY Major Chemicals
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- CNEY Industrials
- PTIX Health Care
- Exchange
- CNEY Nasdaq
- PTIX Nasdaq
- Market Cap
- CNEY 2.1M
- PTIX 1.9M
- IPO Year
- CNEY 2021
- PTIX 2016
- Fundamental
- Price
- CNEY $0.12
- PTIX $3.03
- Analyst Decision
- CNEY
- PTIX
- Analyst Count
- CNEY 0
- PTIX 0
- Target Price
- CNEY N/A
- PTIX N/A
- AVG Volume (30 Days)
- CNEY 36.0M
- PTIX 259.3K
- Earning Date
- CNEY 01-01-0001
- PTIX 05-27-2025
- Dividend Yield
- CNEY N/A
- PTIX N/A
- EPS Growth
- CNEY N/A
- PTIX N/A
- EPS
- CNEY N/A
- PTIX N/A
- Revenue
- CNEY $50,957,974.00
- PTIX N/A
- Revenue This Year
- CNEY N/A
- PTIX N/A
- Revenue Next Year
- CNEY N/A
- PTIX N/A
- P/E Ratio
- CNEY N/A
- PTIX N/A
- Revenue Growth
- CNEY N/A
- PTIX N/A
- 52 Week Low
- CNEY $0.11
- PTIX $2.51
- 52 Week High
- CNEY $1.60
- PTIX $26.18
- Technical
- Relative Strength Index (RSI)
- CNEY 37.87
- PTIX 45.51
- Support Level
- CNEY $0.16
- PTIX $2.82
- Resistance Level
- CNEY $0.29
- PTIX $3.68
- Average True Range (ATR)
- CNEY 0.04
- PTIX 0.54
- MACD
- CNEY -0.00
- PTIX 0.03
- Stochastic Oscillator
- CNEY 0.56
- PTIX 37.16
About CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.